Breaking
Telix Acquires ITM in $2.35 Billion Deal, Forging a Radiopharmaceutical Powerhouse in Cancer Treatment
Vitamin D2 Supplements May Undermine the Body’s Preferred Vitamin D Form, New Research Suggests
Bradyzoite subtypes rule the crossroads of Toxoplasma development
Glamorama Makes a Triumphant Return to Minneapolis Benefiting Children’s Cancer Research Fund
Welcoming Three New Leaders to the CureSearch Board of Directors
A Pan-Canadian Team Develops Revolutionary Egg-Based Tumor Model for Rapid, Personalized Cancer Treatment Discovery
Estrogen Hormone Regulates Female Binge Drinking, Driving Rapid Alcohol Consumption and Contributing to Sex Differences in Behavior
Routine Calcium and Vitamin D Supplementation Offers Little Benefit Against Falls and Fractures for Most Older Adults, Major Review Concludes
The Dual Nature of a Crucial Enzyme: PI3K Possesses Both Accelerator and Brake for Cell Migration
Genetically Tailored Treatment Plans for Children with Wilms Tumour Promise More Effective Care and Minimized Side Effects
21 Sep 2026, Mon

Hendra Lukman

You Missed

Biotech, Pharma & Cancer Drug Development

Telix Acquires ITM in $2.35 Billion Deal, Forging a Radiopharmaceutical Powerhouse in Cancer Treatment

Hematology, Leukemia & Lymphoma

Vitamin D2 Supplements May Undermine the Body’s Preferred Vitamin D Form, New Research Suggests

Gynecologic Oncology (Ovarian, Cervical)

Bradyzoite subtypes rule the crossroads of Toxoplasma development

Pediatric Oncology & Childhood Cancers

Glamorama Makes a Triumphant Return to Minneapolis Benefiting Children’s Cancer Research Fund